Workday, Inc.
$40.62B- Market cap
- $43.07B
- Debt
- +$2.99B
- Cash
- −$5.44B
Capital structure 94% equity / 6% debt · EV / Revenue 4.25x · EV / EBITDA 29.95x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $43.07B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: WDAY stock price vs ALNY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Needs ALNY P/E.
Implied fair value · at WDAY's multiple
Needs WDAY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: WDAY FY 2026 (ended Jan 31, 2026) · ALNY FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 4.25x · EV / EBITDA 29.95x
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
WDAY carries the larger enterprise value at $40.62B against $38.07B; WDAY trades on the lower EV / Revenue multiple (4.25x vs 10.25x); WDAY on the lower EV / EBITDA (29.95x vs 63.81x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
WORKDAY, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.38x
5.22x
Net debt / EBITDA
Leverage against operating earnings
-1.81x
4.13x
Cash and equivalents
Liquid reserves on the balance sheet
$5.44B
$1.66B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Salesforce, Inc.
WDAY vs CRM
Oracle Corporation
WDAY vs ORCL
INTUIT INC.
WDAY vs INTU
AUTOMATIC DATA PROCESSING INC
WDAY vs ADP
Paycom Software, Inc.
WDAY vs PAYC
Moderna, Inc.
WDAY vs MRNA
Sarepta Therapeutics, Inc.
WDAY vs SRPT
VERTEX PHARMACEUTICALS INC / MA
WDAY vs VRTX
BioNTech SE
WDAY vs BNTX
ACADIA PHARMACEUTICALS INC
WDAY vs ACAD
$2.99B
$4.12B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.